[1] ZENG Q, LI N, WANG Q, et al. The Prevalence of Osteoporosis in China, a Nationwide, Multicenter DXA Survey. J Bone Miner Res. 2019;34(10): 1789-1797.
[2] SIPILÄ S, TÖRMÄKANGAS T, SILLANPÄÄ E, et al. Muscle and bone mass in middle-aged women: role of menopausal status and physical activity. J Cachexia Sarcopenia Muscle. 2020;11(3):698-709.
[3] CHEN CH, WANG L, SERDAR TULU U, et al. An osteopenic/osteoporotic phenotype delays alveolar bone repair. Bone. 2018;112:212-219.
[4] WAGNER F, SCHUDER K, HOF M, et al. Does osteoporosis influence the marginal peri-implant bone level in female patients? A cross-sectional study in a matched collective. Clin Implant Dent Relat Res. 2017;19(4): 616-623.
[5] JEFFCOAT MK, LEWIS CE, REDDY MS, et al. Post-menopausal bone loss and its relationship to oral bone loss. Periodontol 2000. 2000;23:94-102.
[6] ORYAN A,SAHVIEH S. Effects of bisphosphonates on osteoporosis: Focus on zoledronate. Life Sci. 2021;264:118681.
[7] ZHOU W, LIU Y, GUO X, et al. Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis. Osteoporos Int. 2019;30(8):1581-1589.
[8] EVANGELATOS G, FRAGOULIS GE, ANASTASILAKIS AD, et al. Zoledronic acid is effective in the management of migratory osteoporosis unresponsive to conservative treatment and risedronate: A case report. J Musculoskelet Neuronal Interact. 2021;21(1):138-141.
[9] LIU Z, LI CW, MAO YF, et al. Study on Zoledronic Acid Reducing Acute Bone Loss and Fracture Rates in Elderly Postoperative Patients with Intertrochanteric Fractures. Orthop Surg. 2019;11(3):380-385.
[10] GAO SY, ZHENG GS, WANG L, et al. Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB. PLoS One. 2017;12(6):e0179248.
[11] PAN WL, CHEN PL, LIN CY, et al. Strontium ranelate treatment in a postmenopausal woman with osteonecrosis of the jaw after long-term oral bisphosphonate administration: a case report. Clin Interv Aging. 2017;12:1089-1093.
[12] HAIDAR A, JøNLER M, FOLKMAR TB, et al. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw. Scand J Urol Nephrol. 2009; 43(6):442-444.
[13] 程余婷, 伍超, 黄晓林, 等. 低剂量唑来膦酸对去势拔牙大鼠破骨及成骨细胞的影响[J]. 中国组织工程研究,2020,24(17):2686-2693.
[14] 黄晓林, 廖健, 洪伟, 等. 破骨细胞形成过程中唑来膦酸的作用途径及机制[J]. 中国组织工程研究,2019,23(17):2716-2721.
[15] HUANG XL, HUANG LY, CHENG YT, et al. Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-kappaB and JNK signalling pathways. Int J Mol Med. 2019;44(2):582-592.
[16] YOUM YH, GRANT RW, MCCABE LR, et al. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab. 2013;18(4):519-532.
[17] WANG L, HAUENSTEIN AV. The NLRP3 inflammasome: Mechanism of action, role in disease and therapies. Mol Aspects Med. 2020;76: 100889.
[18] MURAKAMI T, TAKAHATA Y, HATA K, et al. Role of interleukin-1 and inflammasomes in oral disease. J Oral Biosci. 2020;62(3):242-248.
[19] OHORI F, KITAURA H, OGAWA S, et al. IL-33 Inhibits TNF-α-Induced Osteoclastogenesis and Bone Resorption. Int J Mol Sci. 2020;21(3):1130.
[20] ARITA Y, YOSHINAGA Y, KANEKO T, et al. Glyburide inhibits the bone resorption induced by traumatic occlusion in rats. J Periodontal Res. 2020;55(3):464-471.
[21] BAUERNFEIND FG, HORVATH G, STUTZ A, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183(2):787-791.
[22] ALIPPE Y, WANG C, RICCI B, et al. Bone matrix components activate the NLRP3 inflammasome and promote osteoclast differentiation. Sci Rep. 2017;7(1):6630.
[23] EPSLEY S, TADROS S, FARID A, et al. The effect of inflammation on bone. Front Physiol. 2020;11:511799.
[24] KELLEY N, JELTEMA D, DUAN Y, et al. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019;20(13):3328.
[25] YOUSEFZADEH N, KASHFI K, JEDDI S, et al. Ovariectomized rat model of osteoporosis: a practical guide. Excli J. 2020;19:89-107.
[26] 许良中,杨文涛. 免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231.
[27] ZHOU L, FENG Y, JIN Y, et al. Verbascoside promotes apoptosis by regulating HIPK2-p53 signaling in human colorectal cancer. BMC Cancer. 2014;14:747.
[28] RUCHLEMER R, AMIT-KOHN M, TVITO A, et al. Bone loss and hematological malignancies in adults: a pilot study. Support Care Cancer. 2018;26(9): 3013-3020.
[29] DEREKA X, CALCIOLARI E, DONOS N, et al. Osseointegration in osteoporotic-like condition: A systematic review of preclinical studies. J Periodontal Res. 2018;53(6): 933-940.
[30] GIRO G, CHAMBRONE L, GOLDSTEIN A, et al. Impact of osteoporosis in dental implants: A systematic review. World J Orthop. 2015;6(2):311-315.
[31] SCHULZ MC, KOWALD J, ESTENFELDER S, et al. Site-Specific Variations in Bone Mineral Density under Systemic Conditions Inducing Osteoporosis in Minipigs. Front Physiol. 2017;8:426.
[32] JOHNSTON BD,WARD WE. The ovariectomized rat as a model for studying alveolar bone loss in postmenopausal women. Biomed Res Int. 2015;2015:635023.
[33] EVANGELATOS G, FRAGOULIS GE, ZAMPELI E, et al. Zoledronic acid is effective and safe in migratory osteoporosis. Rheumatology (Oxford). 2020;59(2):439-440.
[34] MARUOTTI N, CORRADO A, NEVE A, et al. Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol. 2012;68(7):1013-1018.
[35] 李颉颃, 苏志飞, 白璇, 等. 唑来膦酸对大鼠骨髓间充质干细胞增殖及成骨分化的作用研究[J]. 华西口腔医学杂志,2019,37(3):242-247.
[36] TENENBAUM HC, TORONTALI M,SUKHU B. Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro. Bone. 1992; 13(3):249-255.
[37] OCHIAI H, OKADA S, SAITO A, et al. Inhibition of insulin-like growth factor-1 (IGF-1) expression by prolonged transforming growth factor-β1 (TGF-β1) administration suppresses osteoblast differentiation. J Biol Chem. 2012;287(27):22654-22661.
[38] REID IR, HORNE AM, MIHOV B, et al. Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial. J Intern Med. 2019; 286(2):221-229.
[39] GHAZALI N, COLLYER JC,TIGHE JV. Hemimandibulectomy and vascularized fibula flap in bisphosphonate-induced mandibular osteonecrosis with polycythaemia rubra vera. Int J Oral Maxillofac Surg. 2013;42(1):120-123.
[40] ANASTASILAKIS AD, PAPAPOULOS SE, POLYZOS SA, et al. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. J Bone Miner Res. 2019; 34(12):2220-2228.
[41] YING G, BO L, YANJUN J, et al. Effect of a local, one time, low-dose injection of zoledronic acid on titanium implant osseointegration in ovariectomized rats. Arch Med Sci. 2016;12(5):941-949.
[42] TüRKER M, ASLAN A, ÇıRPAR M, et al. Histological and biomechanical effects of zoledronate on fracture healing in an osteoporotic rat tibia model. Eklem Hastalik Cerrahisi. 2016;27(1):9-15.
[43] ZHU K, ZHANG J, ZHANG C, et al. Therapeutic efficacy of zoledronic acid combined with calcitriol in elderly patients receiving total hip arthroplasty or hemiarthroplasty for osteoporotic femoral neck fracture. Osteoporos Int. 2021;32(3):559-564.
[44] LEE C, LEE JH, HAN SS, et al. Site-specific and time-course changes of postmenopausal osteoporosis in rat mandible: comparative study with femur. Sci Rep. 2019;9(1):14155.
[45] CHENG YT, LIAO J, ZHOU Q, et al. Zoledronic acid modulates osteoclast apoptosis through activation of the NF-κB signaling pathway in ovariectomized rats. Exp Biol Med (Maywood). 2021;246(15):1727-1739.
[46] NAPETSCHNIG J, WU H. Molecular basis of NF-κB signaling. Annu Rev Biophys. 2013;42:443-468.
[47] ZANG Y, SONG JH, OH SH, et al. Targeting NLRP3 Inflammasome Reduces Age-Related Experimental Alveolar Bone Loss. J Dent Res. 2020;99(11):1287-1295.
[48] SHIRATORI T, KYUMOTO-NAKAMURA Y, KUKITA A, et al. IL-1β Induces Pathologically Activated Osteoclasts Bearing Extremely High Levels of Resorbing Activity: A Possible Pathological Subpopulation of Osteoclasts, Accompanied by Suppressed Expression of Kindlin-3 and Talin-1. J Immunol. 2018;200(1):218-228. |